Soluble urokinase plasminogen activator receptor (suPAR) is lower in disease-free patients but cannot rule out incident disease in patients with suspected cancer.

CONCLUSIONS: suPAR was significantly lower in disease-free individuals compared to patients with cancer or other conditions, but the PPV was not sufficiently high to terminate further clinical investigation with appropriate safety. Elevated suPAR may be a useful prognostic marker for adverse outcomes.
PMID: 32504704 [PubMed - as supplied by publisher]

Source: Clinical Biochemistry - June 2, 2020 Category: Biochemistry Authors: J H Rasmussen L, Schultz M, Iversen K, Eugen-Olsen J, Helms M, David K, Kjaer A, Lebech AM, Kronborg G Tags: Clin Biochem Source Type: research